Last Updated: January 19, 2022


Featured Articles

Updates in the Pipeline of HIV Therapy

Infectious Disease Special Edition | January 14, 2022

NIH celebrates FDA approval of long-acting injectable drug for HIV prevention

NIH | December 21, 2021

FDA Approves APRETUDE (cabotegravir) for HIV-1 Pre-Exposure Prophylaxis

FDA | December 20, 2021

TAG’s 2021 Pipeline Report: The Latest in HIV and HCV R&D

Treatment Action Group | October 2021

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

AIDSinfo | August 16, 2021

At Last, Generic HIV Prevention Drugs Promise Savings And Access—But Also Reveal Precarious Financing

Health Affairs | May 20, 2021

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

aidsinfo | February 10, 2021

Novel Antiretroviral Agents

Current HIV/AIDS Reports Feb 2020

IAS Panel Releases Updated 2020 Guidelines on ART and HIV Prevention 

Infectious Disease Advisor | December 4, 2020

Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website

Department of Pharmacology & Therapeutics, University of Liverpool

Proportion of serious drug interactions dropping on Liverpool antiretroviral website

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

HIV/AIDS Update- Prezista (darunavir) labeling changes
News Updates

HIV Provider Organization to Launch New Web Resource on Long-Acting Agents

American Academy of HIV Medicine | January 6, 2022

Dolutegravir-Based Treatment More Effective in Children Living With HIV

Contagion Live | January 6, 2022

Outcomes of Dolutegravir Treatment in Patients With HIV Infection Who Failed Antiretroviral Therapy 

Infectious Disease Advisor | January 5, 2022

HIV Drug Resistance Report - November 2021

ReliefWeb | November 24, 2021

Injectable HIV treatment for patients in UK | HIV AIDS | Health News 

YouTube | November 22, 2021

Clinics will need new systems to administer injectable HIV therapies, says Canadian early adopter 

Aidsmap | November 5, 2021

Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma

NIH | November 4, 2021

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

NATAP | October 26, 2021

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results 

AIDS. 2021 Oct 13. doi: 10.1097/QAD.0000000000003085.

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

ViiV | 28 September 2021

The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis

Antivir Ther. 2020;25(1):21-32. doi: 10.3851/IMP3346

FDA Approves Pfizer Booster Shots for Seniors, High-Risk Americans

docwirenews | September 23, 2021

Agents Used in Antiretroviral Therapy

Clinical Care Options | September 2021

Researchers advance the use of nanoparticles to deliver HIV/AIDS drugs to the brain

FIU News | September 17, 2021

First-in-Class NRTTI Demonstrates Potential as Long-Acting Oral PrEP Against HIV | September 10, 2021

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

Open Forum Infect Dis. 2021 Aug 25;8(9):ofab439. doi: 10.1093/ofid/ofab439. eCollection 2021 Sep.

Direct oral anticoagulants versus warfarin in people living with human immunodeficiency virus 

Int J STD AIDS. 2021 Jul 23;9564624211031728. doi: 10.1177/09564624211031728

Changes to the Epclusa product label for use in pediatrics

FDA | June 2021

Changes to the Mavyret product labeling for use in pediatrics

FDA | June 2021

How modern medication has extended the life span of people with HIV over the past 40 years 

California News Times | May 2021

Six drugmakers are in violation of 340B statute, says HRSA 

Healthcare Finance News | May 18, 2021

Clinical Insights into New Treatment Options for HIV: Cabenuva and Vocabria 

Pharmacy Times | May 10, 2021

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

Business Wire | May 4, 2021


  2019 Archives 2020 Archives 2021 Archives